DRUGS & SUPPLEMENTS

Clottagen

Name: Clottagen drug & pharmaceuticals. Available Forms, Doses, Prices
Creator: sdrugs.com
Published: 2021-11-11T10:10:10+00:00

What is the dose of the medication you are taking?

Clottagen uses

Indications and usage
Dosage and administration
Dosage forms and strengths
Contraindications
Warnings and precautions
Adverse reactions
Use in specific populations
Description
Clinical pharmacology
Clinical studies
References
How supplied/storage and handling
Patient counseling information
Clottagen reviews

1 INDICATIONS AND USAGE

Clottagen^®, Fibrinogen Concentrate (Human) is a human blood coagulation factor indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

Clottagen, Fibrinogen Concentrate (Human) is a human blood coagulation factor indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. (1)

2 DOSAGE AND ADMINISTRATION

For intravenous use only.

Dose =

[Target level (mg/dL) - measured level (mg/dL)]
1.7 (mg/dL per mg/kg body weight)
Dose when fibrinogen level is unknown: 70 mg/kg body weight. (2.1)
Monitoring of patient's fibrinogen level is recommended during treatment. A target fibrinogen level of 100 mg/dL should be maintained until hemostasis is obtained. (2.1)
Injection rate should not exceed 5 mL per minute. (2.3)

2.1 Treatment of Congenital Fibrinogen Deficiency

Clottagen dosing, duration of dosing and frequency of administration should be individualized based on the extent of bleeding, laboratory values, and the clinical condition of the patient.

Clottagen dose when baseline fibrinogen level is known.

Dose should be individually calculated for each patient based on the target plasma fibrinogen level based on the type of bleeding, actual measured plasma fibrinogen level and body weight, using the following formula [see Clinical Pharmacology (12.3) ]:

[Target level (mg/dL) - measured level (mg/dL)]

1.7 (mg/dL per mg/kg body weight)

Clottagen dose when baseline fibrinogen level is not known.

If the patient's fibrinogen level is not known, the recommended dose is 70 mg per kg of body weight administered intravenously.

Monitor patient's fibrinogen level during treatment with Clottagen. Maintain a target fibrinogen level of 100 mg/dL until hemostasis is obtained.

2.2 Preparation and Reconstitution

The procedures below are provided as general guidelines for preparation and reconstitution of Clottagen.

Use aseptic technique when preparing and reconstituting Clottagen.

Reconstitute Clottagen at room temperature as follows:

Remove the cap from the product vial to expose the central portion of the rubber stopper.
Clean the surface of the rubber stopper with an antiseptic solution and allow it to dry.
Using an appropriate transfer device or syringe, transfer 50 mL of Sterile Water for Injection into the product vial.
Gently swirl the product vial to ensure the product is fully dissolved. Do not shake the vial.

After reconstitution, the Clottagen solution should be colorless and clear to slightly opalescent. Inspect visually for particulate matter and discoloration prior to administration. Do not use if the solution is cloudy or contains particulates. Discard partially used vials.

Clottagen is stable for 8 hours after reconstitution when stored at 20-25°C; administer within this time period.

2.3 Administration

Do not mix Clottagen with other medicinal products or intravenous solutions. Administer through a separate injection site.

Use aseptic technique when administering Clottagen.

Administer Clottagen at room temperature by slow intravenous injection at a rate not exceeding 5 mL per minute.

3 DOSAGE FORMS AND STRENGTHS

Clottagen is available as a single-use vial containing 900 mg to 1300 mg lyophilized fibrinogen concentrate powder for reconstitution with 50 mL of Sterile Water for Injection.

The actual fibrinogen potency for each lot is printed on the vial label and carton.

Clottagen is available as a single-use vial containing 900 mg to 1300 mg lyophilized fibrinogen concentrate powder for reconstitution. (3)
The actual fibrinogen potency for each lot is printed on the vial label and carton. (3)

4 CONTRAINDICATIONS

Clottagen is contraindicated in patients with known anaphylactic or severe systemic reactions to human plasma-derived products .

Known anaphylactic or severe systemic reactions to human plasma-derived products (4)

5 WARNINGS AND PRECAUTIONS

Monitor patients for early signs of anaphylaxis or hypersensitivity reactions and if necessary, discontinue administration and institute appropriate treatment.
Thrombotic events have been reported in patients receiving Clottagen. Weigh the benefits of administration versus the risks of thrombosis. (5.2)
Clottagen is made from pooled human plasma. Products made from human plasma may contain infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. (5.3)

5.1 Hypersensitivity Reactions

Allergic reactions may occur. If signs or symptoms of anaphylaxis or hypersensitivity reactions (including hives, generalized urticaria, tightness of the chest, wheezing, hypotension) occur, immediately discontinue administration . The treatment required depends on the nature and severity of the reaction.

5.2 Thrombosis

Thrombosis may occur spontaneously in patients with congenital fibrinogen deficiency with or without the use of fibrinogen replacement therapy.¹ Thromboembolic events have been reported in patients treated with Clottagen. Weigh the benefits of Clottagen administration versus the risk of thrombosis. Monitor patients receiving Clottagen for signs and symptoms of thrombosis.

5.3 Transmissible Infectious Agents

Clottagen is made from human plasma. Products made from human plasma may contain infectious agents (e.g., viruses and theoretically the Creutzfeldt-Jakob disease agent [CJD]) that can cause disease. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by a process demonstrated to inactivate and/or remove certain viruses during manufacturing . Despite these measures, such products may still potentially transmit disease. There is also the possibility that unknown infectious agents may be present in such products . All infections thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to CSL Behring Pharmacovigilance at 1-866-915-6958.

6 ADVERSE REACTIONS

The most serious adverse reactions reported in clinical studies or through postmarketing surveillance following Clottagen treatment are thromboembolic episodes, including myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis, and allergic-anaphylactic reactions.

The most common adverse reactions observed in more than one subject in clinical studies were fever and headache.

The most serious adverse reactions observed are thrombotic episodes (pulmonary embolism, myocardial infarction, deep vein thrombosis) and anaphylactic reactions. (6)
The most common adverse reactions observed in clinical studies (frequency >1%) were fever and headache. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact CSL Behring at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in practice.

6.2 Postmarketing Experience

Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure.

The following adverse reactions, identified by system organ class, have shown a possible causal relationship with Clottagen.

Allergic-anaphylactic reactions: anaphylaxis, dyspnea, rash
Cardiovascular: thromboembolic complications such as myocardial infarction, pulmonary embolism, and deep vein thrombosis
General/Body as a Whole: chills, nausea, vomiting

8 USE IN SPECIFIC POPULATIONS

Pediatric: Shorter half-life and faster clearance than in adults has been observed.

8.1 Pregnancy

Risk Summary

There are no studies of Clottagen use in pregnant women. Animal reproduction studies have not been conducted with Clottagen. It is not known whether Clottagen can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Clottagen should be used during pregnancy only if clearly needed. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

8.2 Lactation

Risk Summary

There is no information regarding the presence of Clottagen in human milk, its effects on the breastfed infant, or its effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Clottagen and any potential adverse effects on the breastfed infant from Clottagen or from the underlying maternal condition.

8.4 Pediatric Use

Clottagen studies have included subjects below the age of 16 years. In the pharmacokinetic study , 2 children aged 8 and 11 years and 3 adolescents aged 12, 14 and 16 years were studied. Subjects <16 years of age (n = 4) had shorter half-life (69.9 ± 8.5 h) and faster clearance (0.7 ± 0.1 mg/L) compared with adults (half-life: 82.3 ± 20.0 h, clearance: 0.53 ± 0.1 mg/L). The number of subjects <16 years of age in this study limits statistical interpretation.

8.5 Geriatric Use

The safety and efficacy of Clottagen in the geriatric population has not been studied. There were an insufficient number of subjects in this age group to determine whether they respond differently from younger subjects.

11 DESCRIPTION

Clottagen is a sterile, heat-treated, lyophilized fibrinogen (coagulation factor I) concentrate powder manufactured from pooled human plasma.

Fibrinogen (factor I) is a soluble plasma glycoprotein with a molecular weight of about 340 kDa. The native molecule is a dimer and consists of three pairs of polypeptide chains (Aα, Bβ and γ). Fibrinogen is a physiological substrate of three enzymes: thrombin, factor XIIIa, and plasmin.

Each vial contains 900 to 1300 mg fibrinogen, 400 to 700 mg human albumin, 375 to 660 mg L-arginine hydrochloride, 200 to 350 mg sodium chloride and 50 to 100 mg sodium citrate. Sodium hydroxide and hydrochloric acid may have been used to adjust the pH. The pH of the reconstituted Clottagen is in a range of 6.5 to 7.5.

Viral Clearance

All plasma used in the manufacture of Clottagen is tested using serological assays for hepatitis B surface antigen and for antibodies to Human Immunodeficiency Virus (HIV)-1/2 and Hepatitis C Virus (HCV). As an additional safety measure, the plasma is tested with Nucleic Acid Testing (NAT) for Hepatitis B Virus (HBV), HCV and HIV-1 and found to be non-reactive (negative). The plasma is also screened for Hepatitis A Virus (HAV) and Human Parvovirus B19 (B19V) by NAT. Only plasma that passed virus screening is used for production, and the limit for B19V in the fractionation pool is set not to exceed 10⁴ IU of B19V DNA per mL.

Clottagen is manufactured from cryoprecipitate into a glycine precipitate, which is then further purified by multiple precipitation/adsorption steps. The manufacturing process has been demonstrated to reduce the risk of virus transmission in an additive manner: cryoprecipitation, heat treatment (+60ºC for 20 hours in an aqueous solution), two subsequent glycine precipitation steps (initial and main glycine precipitation steps), and lyophilization. These steps have been validated independently in a series of in vitro experiments for their capacity to inactivate and/or remove both enveloped and non-enveloped viruses. The results of virus clearance validation studies for Clottagen manufacturing process are summarized in Table 1.

Manufacturing Step	Virus Reduction Factor (log₁₀)
	Enveloped viruses				Non-enveloped viruses
	HIVHIV, human immunodeficiency virus, a model for HIV-1 and HIV-2	BVDVBVDV, bovine viral diarrhea virus, a model for Hepatitis C virus (HCV) and West Nile Virus (WNV)	WNVWNV, West Nile virus	PRVPRV, Pseudorabies virus, a model for large enveloped DNA viruses	HAVHAV, Hepatitis A virus	CPVCPV, canine parvovirus, a model for B19V
Studies using human parvovirus B19, which are considered experimental in nature, have demonstrated a virus reduction factor of ≥4.5 log10 by heat treatment
n.d. not determined
Cryoprecipitation	n.d.	n.d.	n.d.	1.6	n.d.	1.9
Heat Treatment	≥5.7	≥9.1	≥8.3	5.4	5.9	1.4
Glycine precipitations (two subsequent steps)	3.9	2.1	n.d.	1.8	1.0	1.6
Lyophilization	n.d.	n.d.	n.d.	n.d.	1.7	n.d.
Cumulative virus reduction (log10)	≥9.6	≥11.2	≥8.3	8.8	8.6	4.9

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

During the coagulation process, thrombin cleaves the Aα and Bβ chains releasing fibrinopeptides A and B.² FPA is separated rapidly and the remaining molecule is a soluble fibrin monomer (fibrin I). The slower removal of FPB results in formation of fibrin II that is capable of polymerization that occurs by aggregation of fibrin monomers. ² The resulting fibrin is stabilized in the presence of calcium ions and by activated factor XIII, which acts as a transglutaminase. Factor XIIIa-induced cross-linking of fibrin polymers renders the fibrin clot more elastic and more resistant to fibrinolysis.³ Cross-linked fibrin is the end result of the coagulation cascade, and provides tensile strength to a primary hemostatic platelet plug and structure to the vessel wall.

12.2 Pharmacodynamic Action

Administration of Clottagen to patients with congenital fibrinogen deficiency replaces missing or low levels of coagulation factor. Normal levels are in the range of 200 to 450 mg/dL.⁴

12.3 Pharmacokinetics

A prospective, open label, uncontrolled, multicenter pharmacokinetic study was conducted in 5 females and 9 males with congenital fibrinogen deficiency (afibrinogenemia), ranging in age from 8 to 61 years (2 children, 3 adolescents, 9 adults). Each subject received a single intravenous dose of 70 mg/kg Clottagen. Blood samples were collected to determine fibrinogen activity at baseline and up to 14 days after infusion. The pharmacokinetic parameters of Clottagen are summarized in Table 2.

No statistically relevant difference in fibrinogen activity was observed between males and females. Subjects <16 years of age (n=4) had shorter half-life (69.9 ± 8.5 h) and faster clearance (0.73 ± 0.14 mg/L) compared with subjects ≥16 years of age (half-life of 82.5 ± 20.0 h and clearance of 0.53 ± 0.07 mg/L). The number of subjects <16 years of age in this study limits statistical interpretation.

The incremental in vivo recovery (IVR) was determined from levels obtained up to 4 hours post-infusion. The median incremental IVR was 1.7 mg/dL (range 1.30 – 2.73 mg/dL) increase per mg/kg. The median in vivo recovery indicates that a dose of 70 mg/kg will increase fibrinogen plasma concentration in patients by approximately 120 mg/dL.

The pharmacokinetic analysis using fibrinogen antigen data (ELISA) was concordant with the fibrinogen activity (Clauss assay).

Parameters	Mean ± SD (range)
Half-life [hours]	78.7 ± 18.13 (55.73-117.26)
C_max [mg/dL]	140 ± 27 (100-210)
AUC for dose of 70 mg/kg [mg*hr/mL]	124.3 ± 24.16 (81.73-156.40)
Clearance [mL/h/kg]	0.59 ± 0.13 (0.45-0.86)
Mean residence time [hours]	92.8 ± 20.11 (66.14-126.44)
Volume of distribution at steady state [mL/kg]	52.7 ± 7.48 (36.22-67.67)

14 CLINICAL STUDIES

The efficacy of Clottagen is based on maximum clot firmness, a measure of clot structural integrity that reflects the underlying effectiveness of the fibrinogen present to form a fibrin clot. A pharmacokinetic study evaluated single-dose PK and maximum clot firmness (MCF) in subjects with afibrinogenemia. MCF was determined by thromboelastometry (ROTEM) testing and was used to demonstrate functional activity of replacement fibrinogen when a fixed dose of Clottagen was administered. Clot firmness is a functional parameter that depends on activation of coagulation, fibrinogen content of the sample and polymerization/crosslinking of the fibrin network. Thromboelastometry has been shown to be a functional marker for assessment of fibrinogen content and for effects of fibrinogen supplementation on clinical efficacy.⁵

For each subject, MCF was determined before (baseline) and one hour after single dose administration of Clottagen. Clottagen was found to be effective in increasing clot firmness in subjects with congenital fibrinogen deficiency (afibrinogenemia) as measured by thromboelastometry. The study results demonstrated that MCF values were significantly higher after administration of Clottagen than at baseline. Mean change from pre-infusion to 1 hour post-infusion was 8.9 mm in the primary analysis (9.9 mm for subjects <16years old and 8.5 mm for subjects ≥16 to <65 years old). Mean change in MCF values closely approximated levels expected from adding known amounts of fibrinogen to plasma in vitro.⁶

Time point	n	Mean ± SD	Median (range)
MCF = maximum clot firmness; mm = millimeter; ITT = intention-to-treat.
Pre-infusion	13	0 ± 0	0 (0-0)
1 hour post-infusion	13	10.3 ± 2.7	10.0 (6.5-16.5)
Mean change (primary analysis)p-value was <0.0001.	15The mean change was set to 0 for 2 subjects with missing MCF data.	8.9 ± 4.4	9.5 (0-16.5)

15 REFERENCES

Peyvandi F, Haertal S, Knaub S, et al. Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. J Thromb Haemost 2006; 4:1634-7.
Kreuz W, Meili E, Peter-Salonen K, et al. Pharmacokinetic properties of a pasteurized fibrinogen concentrate. Transfusion and Apheresis Science 2005; 32:239-46.
Colman R, Clowes A, George J, et al. Overview of Hemostasis. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice (5^th ed.). Colman R, Clowes A, George J, Goldhaber S, Marder VJ (eds.). Lippincott Williams & Wilkins, Philadelphia 2006:11-14.
Kreuz W, Meili E, Peter-Salonen K, et al. Efficacy and tolerability of a pasteurized human fibrinogen concentrate in patients with congenital fibrinogen deficiency. Transfusion and Apheresis Science 2005; 32:247-253.
Fries D, Innerhofer P, Reif C, et al. The Effect of Fibrinogen Substitution on Reversal of Dilutional Coagulopathy: An In Vitro Model. Anesth Analg 2006; 102:347-351.
Kalina U, Stöhr HA, Bickhard H, et. al. Rotational thromboelastography for monitoring of fibrinogen concentrate therapy in fibrinogen deficiency. Blood Coagulation and Fibrinolysis. 2008; 19:777-783.

16 HOW SUPPLIED/STORAGE AND HANDLING

Clottagen is supplied in a single-use vial.
Each carton contains one vial of Clottagen.
Components are not made with natural rubber latex.
Clottagen contains no preservative.
The actual potency of fibrinogen concentrate in milligram (mg) is stated on each Clottagen vial label and carton.

The product presentation includes a package insert and the following component:

Presentation	Carton NDC Number	Component
900-1300 mg	63833-891-51	Clottagen in a single-use vial (NDC 63833-891-90)

When stored at temperatures of 2-25°C (36-77°F), Clottagen is stable for the period indicated by the expiration date on the carton and vial label (up to 60 months). Do not use Clottagen beyond the expiration date.
Keep Clottagen in its original carton until ready to use.
Do not freeze. Protect from light.

17 PATIENT COUNSELING INFORMATION

Allergic Reactions
Inform patients of the early signs of allergic or hypersensitivity reactions to Clottagen, including hives, chest tightness, wheezing, hypotension, and anaphylaxis. Advise them to notify their physician immediately if they experience any of these symptoms .

Thrombosis
Inform patients that thrombosis with or without embolization has been reported with the use of Clottagen. Any symptoms of thrombotic events such as unexplained pleuritic, chest and/or leg pain or edema, hemoptysis, dyspnea, tachypnea or unexplained neurologic symptoms should be reported to their physician immediately .

Transmissible Infectious Agents
Inform patients that Clottagen is made from human plasma (part of the blood) and may contain infectious agents that can cause disease (e.g., viruses and, theoretically, the CJD agent). Explain that the risk of transmitting an infection agent using Clottagen has been reduced by screening plasma donors, testing the donated plasma for certain virus infections, and incorporating a process demonstrated to inactivate and/or remove certain viruses during manufacturing. Symptoms of possible virus infection include headache, fever, nausea, vomiting, weakness, malaise, diarrhea, or, in the case of hepatitis, jaundice .

Manufactured by:

CSL Behring GmbH

35041 Marburg Germany

US License No. 1765

Distributed by:

CSL Behring LLC

Kankakee, IL 60901 USA

NDC 63833-891-90

Fibrinogen Concentrate

(Human)

Clottagen ^®

For Intravenous

Administration Only

Manufactured by:

CSL Behring GmbH

35041 Marburg, Germany

US License No. 1765

Distributed by:

CSL Behring LLC

Kankakee, IL 60901 USA

Clottagen pharmaceutical active ingredients containing related brand and generic drugs:

Fibrinogen Human

Clottagen available forms, composition, doses:

Injectable; Injection; Fibrinogen Human 15 mg

Clottagen destination | category:

Human:
Blood plasma glycoproteins
Hemostatics

Clottagen Anatomical Therapeutic Chemical codes:

B02BB01 - Human Fibrinogen
B02BC10 - Fibrinogen, Human

Clottagen pharmaceutical companies:

LFB Biomedicaments

References

Dailymed."RIASTAP (FIBRINOGEN HUMAN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [CSL BEHRING GMBH]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
"Fibrinogen human". https://pubchem.ncbi.nlm.nih.gov/su... (accessed August 28, 2018).
"Fibrinogen Human - DrugBank". http://www.drugbank.ca/drugs/DB0922... (accessed August 28, 2018).

Frequently asked Questions

Can i drive or operate heavy machine after consuming Clottagen?

Depending on the reaction of the Clottagen after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Clottagen not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Is Clottagen addictive or habit forming?

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

Review

sdrugs.com conducted a study on Clottagen, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Clottagen consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.